Bendamustine plus Rituximab Versus R‐CHOP as First‐Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. (9th January 2018)

• Record Type: Journal Article
• Authors: Mondello, Patrizia; Steiner, Normann; Willenbacher, Wolfgang; Cerchione, Claudio; Nappi, Davide; Mauro, Endri; Ferrero, Simone; Cuzzocrea, Salvatore; Mian, Michael
• Is Part Of: Oncologist. Volume 23:Number 4(2018)
• Page Start: 454
• Page End: 460
• Publication Date: 2018-01-09
• Subjects: Follicular lymphoma -- grade 3A -- Bendamustine -- Rituximab; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2017-0037
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract : Background: Rituximab plus bendamustine (R‐B) has been demonstrated to improve outcomes and reduce toxicity compared with rituximab, cyclophosphamide, doxorubicin, and prednisone (R‐CHOP) in follicular lymphoma (FL). Nevertheless, in clinical practice, many centers still prefer R‐CHOP to R‐B in patients with FL grade 3A (FL3A). Therefore, we retrospectively assessed patients with FL3A treated with either R‐CHOP or R‐B in five European cancer centers and compared their outcomes. Materials and Methods: We retrospectively assessed 132 patients affected by FL grade 3A treated with either R‐B or R‐CHOP in the first line and evaluated outcome and toxicity according to the type of treatment. This study included 101 patients who were a subgroup of a previously published cohort. Results: R‐B was less toxic and achieved a similar percentage of complete remissions compared with R‐CHOP (97% vs. 96%, p = .3). During follow‐up, 10 (16%) patients relapsed after R‐B and 29 (41%) after R‐CHOP ( p = .001), leading to a median progression‐free survival (PFS) of 15 versus 11.7 years, respectively ( p = .03). Furthermore, R‐B overcame the negative prognostic impact of BCL2 expression (15 vs. 4.8 years; p = .001). However, median overall survival was similar between both groups (not reached for both; p = .8). Conclusion: R‐B as a first‐line treatment of FL3A is better tolerated than R‐CHOP and seems to induce more profound responses, leading to a significantly lower relapse rate and prolonged PFS. Therefore, R‐B is a valid treatment option for FL grade 3A. Implications for Practice: Rituximab plus bendamustine (R‐B) has shown to be less toxic and more effective than rituximab, cyclophosphamide, doxorubicin, and prednisone (R‐CHOP) in follicular lymphoma grade 3A. Although both regimens can induce a complete remission in >95% of patients, relapses occur more frequently after R‐CHOP than R‐B, leading to a significantly longer progression‐free survival in the latter. R‐B is also able to overcome the impact of negative prognosticators, such as BCL2 expression. However, because of the indolent course of this disease and efficient salvage treatments, overall survival was similar in both treatment groups. Therefore, R‐B is a valid treatment option in this patient setting. Abstract : Follicular lymphoma is the most common indolent lymphoma worldwide. Rituximab plus bendamustine (R‐B) has been shown to improve outcome and reduce toxicity compared with rituximab, cyclophosphamide, doxorubicin, and prednisone (R‐CHOP) in follicular lymphoma; however, in clinical practice in many centers, R‐CHOP is still the preferred treatment. This article reports the results of a study that assessed patients with follicular lymphoma grade 3A treated with either RCHOP or R‐B in five European cancer centers.